Estrogen receptor-positive (ER+) tumors represent the most frequent subtype in breast cancer (BC) across all ages (49) yet unveiling its biology, beyond the estrogenic receptor pathway, has been challenging. This evidence concerns the gene ESR1 and breast carcinoma.